Skip to content

ImmunoCellular Therapeutics, Ltd.

CIK 0000822411

← back to feed
Revenue (TTM)
$0
Q2 Aug 2018
Net Income (TTM)
−$9.28M
+35.2% YoY Q2 Aug 2018
EPS Diluted (TTM)
−$0.03
0.0% YoY Q2 Aug 2018
Gross Margin
—
Q2 Aug 2018
Operating Margin
—
Q2 Aug 2018
Net Margin
—
Q2 Aug 2018
Free Cash Flow (TTM)
−$15.65M
Q2 Aug 2018
Cash
$2.85M
Q2 Aug 2018
Total Debt
$0
Q2 Aug 2018
Shares Outstanding
41.93M sh
Q2 Aug 2018

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings